AstraZeneca: Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in Tropion-Lung01 Phase III Trial
July 04, 2023
July 04, 2023
WILMINGTON, Delaware, July 4 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
First Phase III results for AstraZeneca and Daiichi Sankyo's TROP2-directed antibody drug conjugate demonstrated statistically significant improvement in progression-free survival vs. standard chemotherapy in previously treated locally advanced or metastatic disease
Trial will continue to assess the dual primary endpoint of overall sur . . .
* * *
First Phase III results for AstraZeneca and Daiichi Sankyo's TROP2-directed antibody drug conjugate demonstrated statistically significant improvement in progression-free survival vs. standard chemotherapy in previously treated locally advanced or metastatic disease
Trial will continue to assess the dual primary endpoint of overall sur . . .